Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: Report of two cases

Bone Marrow Transplantation

Volumn 21, Issue 12, 1998, Pages 1271-1274

  Hauke, R J ^a   Greiner, T C ^a   Smir, B N ^a   Vose, J M ^b   Tarantolo, S R ^b   Bashir, R M ^c   Bierman, P J ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Section of Hematology   (United States)

^c Section of Neurological Surgery   (United States)

Author keywords

BMT; EBV; Lymphoproliferation; PTLD

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CASE REPORT; DIFFERENTIAL DIAGNOSIS; EPSTEIN BARR VIRUS; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; LUNG INFILTRATE; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SYMPTOM;

EID: 0031824642     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701258     Document Type: Article

References (27)

1. Penn I. Malignant lymphomas in organ transplant recipients. Transplant Proc 1981; 13: 736-738.
2. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant Jymphoproliferative disorders. Curr Probl Surg 1988; 25: 371-472.
3. van Gorp J, Doornewaard H, Verdorck L et al. Posttransplant T cell lymphoma: report of three cases and a review of the literature. Cancer 1994; 73: 3064-3072.
4. Bierman PJ. Vose JM. Langnas AN et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996; 7: 265-270.
5. Swinnen LJ. Post-transplantation lymphoproliferative disorder. Leuk Lymphoma 1992; 6: 289-297.
6. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381-394.
7. LeBlond V, Sutton L, Dorent R et al. Lymphoproliferative disorder after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961-968.
8. Opelz G, Henderson R. Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516.
9. Brunner FP, Landais P, Selwood NH. Malignancies after renal transplantation: the EDTA-ERA registry experience. Nephro Dial Transplant 1995; 10 (Suppl. 1): 74-80.
10. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
11. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
12. Chao NJ, Berry GJ, Advani R et al. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation 1993; 55: 1425-1428.
13. Shepherd JD, Gascoyne RD, Barnett MJ el al. Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 639-641.
14. Briz M, Fores R, Regidor C et al. Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukemia. Br J Haematol 1997; 98: 485-487.
15. Young L, Alfieri C, Hennessy K et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. New Engl J Med 1989; 321: 1080-1085.
16. Orazi A, Hromas RA, Neiman RS et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997; 107: 419-429.
17. Seiden MV, Sklar J. Molecular genetic analysis of post-transplant lymphoproliferative disorders. Hematol Oncol Clin North Am 1993; 7: 447-465.
18. Penn I. Depressed immunity and the development of cancer. Cancer Detect Prevent 1994; 18: 241-252.
19. List AF, Greco FA, Vogler LB. Lymphoproliferative disease in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987; 5: 1673-1689.
20. Rea D, Delecluse H-J, Hamilton-Dutoit SJ et al. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorder and AIDS-related non-Hodgkin's lymphomas. Ann Oncol 1994; 5 (Suppl. 1): S113-S116.
21. Morris JDH, Eddleston ALWF, Crook T. Viral infection and cancer. Lancet 1995; 346: 745-758.
22. Walker RC. Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder. Transplant Proc 1995; 5 (Suppl. 1): 41.
23. Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc 1995; 5 (Suppl. 1): 38-40.
24. Romagnani S, Ferrini PLR, Ricci M. The immune derangement in Hodgkin's disease. Semin Hematol 1985; 22: 41-55.
25. Kremmer E, Sommer P, Grasser FA. Epstein-Barr virus encoded deoxyuridine triphosphate nucleotidohydrolase (dUTPase): a potential target for drug therapy. Transplant Proc 1997; 29: 812-814.
26. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
27. Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. New Engl J Med 1991; 324: 1451-1456.